相关实验视频

Updated: Sep 19, 2025

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

一个新型的多替代性二甲基基架衍生物类通过向CD155来抑制质母细胞瘤的进展

Yong-Jian Wang¹, Ting Sun¹, Si-Tu Xue¹

¹State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|June 10, 2025

概括

一种新的化合物B7有效地向质母细胞干细胞 (GSCs),并增强自然杀手细胞 (NK) 免疫力. B7通过抑制GSC进展和重塑瘤微环境以治疗质瘤而显示治疗潜力.

科学领域:

神经瘤学神经瘤学
免疫治疗是一种免疫疗法.
药用化学医学化学

背景情况:

质母细胞瘤 (GBM) 是一种高度侵略性的脑瘤,治疗结果不佳.
质母细胞 (GSCs) 是GBM生长和耐药性的关键驱动因素.
向GSC和瘤免疫微环境提供了一个有前途的治疗策略.

研究的目的:

开发针对GBM的新型血脑屏障透化合物.
为了研究一种新型化合物的抗GBM作用和潜在机制,B7.
评估B7对GSC生物学和自然杀手 (NK) 细胞介导免疫的影响.

主要方法:

克洛福克托尔衍生物的结构-活性关系 (SAR) 分析.
在体外和体内评估B7的抗GBM活性.
评估B7对GSC增殖,迁移,入侵和NK细胞细胞毒性的影响.
涉及CD155 (脊髓灰质炎病毒受体) 和其与B7.7相互作用的机制研究.

主要成果:

一种新的血脑屏障透化合物B7被确定具有强大的抗GBM活性.
在体外和体内,B7显著抑制了GSC的增殖,迁移和入侵.
B7增强了NK细胞介导的细胞毒性,并调节了免疫抑制性瘤微环境.
B7通过特定的疏水性相互作用向CD155,影响CD155/TIGIT/CD226通路.

结论:

B7在质母细胞瘤治疗中显示出显著的治疗潜力.
B7协同向GSC生物学和NK细胞免疫.
调节CD155轴是B7抗瘤作用和免疫微环境重塑的关键.

关键词:

质母细胞的干细胞多替代的二甲基衍生物多替代的二甲基衍生物.脊髓灰质炎病毒受体细胞粘附分子 (CD155)瘤免疫微环境是一个微环境.

更多相关视频

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Published on: July 16, 2018

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...